Pharmacogenomics Driving Precision Cancer Medicine is a research paper published in Al-Rafidain Journal of Medical Sciences ( ISSN: 2789-3219 ) (2022). On theSindex it has a DataRank of 0.177. It has been cited 2 times, with 1 citing works in its 1-hop citation network.
Genetically-driven variations in the proteins associated with drug action and adverse effects can lead to a significant influence on cancer therapy. Cancer cells can accumulate a plethora of somatic mutations, beyond any existing germline variants, during their progression from normalcy to malignancy. The narrow therapeutic index that characterises cancer drugs and the life-threatening failure of therapy all point to the importance of considering the inclusion of pharmacogenomics when treating cancers. This narrative review discusses the application, merits and challenges of pharmacogenomics knowledge using a few representative examples. The adoption of a properly considered pharmacogenomic program during cancer treatments can be life-saving and rewarding.
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0.0122
From 1 citing papers with measurable signal
DataRank blends this paper's own citation count with the influence of the papers that cite it. Here, roughly 93% comes from its base citations and 7% from the citation network (1 citing paper contributed measurable signal).
Citers are pulled from OpenAlex sorted by cited_by_count:descand capped per paper, so when the cap binds we keep the highest-signal references and the score is reproducible across reruns.
Click a node to highlight its connections. Use scroll to zoom. Drag to pan.